<DOC>
	<DOCNO>NCT00004578</DOCNO>
	<brief_summary>To assess safety , tolerability antiviral activity lopinavir/ritonavir administer orally antiretroviral-HIV-1 infected subject .</brief_summary>
	<brief_title>ABT-378/Ritonavir Combination With Reverse Transcriptase Inhibitors Antiretroviral Na√Øve HIV-Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria HIV1 positive antiretroviraladult male nonpregnant nonlactating female least 18years old plasma HIV1 RNA &gt; 5000 copies/mL , acutely ill Exclusion Criteria History : prior antiretroviral therapy significant drug hypersensitivity psychiatric illness precludes compliance active substance abuser positive test result drug abuse abnormal lab test result ( hemoglobin , absolute neutrophil count , platelet count , SGPT/AST SGPT/ALT , creatinine , fast triglyceride , significant abnormal ECG result pregnancy lactate female receive another investigational drug within 28 day study initiation unlikely comply unsuitable candidate opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
</DOC>